Use of Serogroup B Meningococcal Vaccines in Persons Aged ≥10 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015
- PMID: 26068564
- PMCID: PMC4584923
Use of Serogroup B Meningococcal Vaccines in Persons Aged ≥10 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015
Erratum in
- MMWR Morb Mortal Wkly Rep. 2015 Jul 31;64(29):806
Abstract
In October 2014, the Food and Drug Administration (FDA) licensed the first serogroup B meningococcal (MenB) vaccine (MenB-FHbp [Trumenba, Wyeth Pharmaceuticals, Inc.]) as a 3-dose series. In January 2015, FDA licensed a second MenB vaccine (MenB-4C [Bexsero, Novartis Vaccines]) as a 2-dose series. Both vaccines were approved for use in persons aged 10-25 years. Following outbreaks of serogroup B meningococcal disease on two college campuses in 2013, both MenB vaccines were granted Breakthrough Therapy designations, which expedites drug development and review by FDA, and were licensed based on accelerated approval regulations. On February 26, 2015, the Advisory Committee on Immunization Practices (ACIP) recommended use of MenB vaccines among certain groups of persons aged ≥10 years who are at increased risk for serogroup B meningococcal disease. This report summarizes information on MenB administration and provides recommendations and guidance for use of these vaccines among persons aged ≥10 years in certain groups who are at increased risk for serogroup B meningococcal disease, and reviews the evidence considered by ACIP to make these recommendations. Recommendations for broader use of MenB vaccines in adolescents and college students will be considered separately by ACIP.
Similar articles
-
Updated Recommendations for Use of MenB-FHbp Serogroup B Meningococcal Vaccine - Advisory Committee on Immunization Practices, 2016.MMWR Morb Mortal Wkly Rep. 2017 May 19;66(19):509-513. doi: 10.15585/mmwr.mm6619a6. MMWR Morb Mortal Wkly Rep. 2017. PMID: 28520709 Free PMC article.
-
Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015.MMWR Morb Mortal Wkly Rep. 2015 Oct 23;64(41):1171-6. doi: 10.15585/mmwr.mm6441a3. MMWR Morb Mortal Wkly Rep. 2015. PMID: 26492381
-
Use of the Pfizer Pentavalent Meningococcal Vaccine Among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.MMWR Morb Mortal Wkly Rep. 2024 Apr 18;73(15):345-350. doi: 10.15585/mmwr.mm7315a4. MMWR Morb Mortal Wkly Rep. 2024. PMID: 38635488 Free PMC article.
-
A review of the immunogenicity, safety and current recommendations for the meningococcal serogroup B vaccine, MenB-FHbp.J Clin Pharm Ther. 2020 Apr;45(2):270-281. doi: 10.1111/jcpt.13083. Epub 2019 Dec 9. J Clin Pharm Ther. 2020. PMID: 31820483 Review.
-
Recommendations for Serogroup B Meningococcal Vaccine for Persons 10 Years and Older.Pediatrics. 2016 Sep;138(3):e20161890. doi: 10.1542/peds.2016-1890. Pediatrics. 2016. PMID: 27573083 Review.
Cited by
-
Epidemic forecast and preparedness for explosive-cerebrospinal meningitis outbreak in Nigeria using the preventive vaccination strategy.Afr J Lab Med. 2023 Nov 17;12(1):2086. doi: 10.4102/ajlm.v12i1.2086. eCollection 2023. Afr J Lab Med. 2023. PMID: 38058850 Free PMC article. Review.
-
Artificial Intelligence-Based Data-Driven Strategy to Accelerate Research, Development, and Clinical Trials of COVID Vaccine.Biomed Res Int. 2022 Jul 6;2022:7205241. doi: 10.1155/2022/7205241. eCollection 2022. Biomed Res Int. 2022. PMID: 35845955 Free PMC article. Review.
-
COVID-19 vaccine design using reverse and structural vaccinology, ontology-based literature mining and machine learning.Brief Bioinform. 2022 Jul 18;23(4):bbac190. doi: 10.1093/bib/bbac190. Brief Bioinform. 2022. PMID: 35649389 Free PMC article.
-
Safety surveillance of meningococcal group B vaccine (Bexsero®), Vaccine Adverse Event Reporting System, 2015-2018.Vaccine. 2022 Jan 21;40(2):247-254. doi: 10.1016/j.vaccine.2021.11.071. Epub 2021 Dec 7. Vaccine. 2022. PMID: 34887130 Free PMC article.
-
Vaccine Design by Reverse Vaccinology and Machine Learning.Methods Mol Biol. 2022;2414:1-16. doi: 10.1007/978-1-0716-1900-1_1. Methods Mol Biol. 2022. PMID: 34784028
References
-
- Food and Drug Administration. CFR - Code of Federal Regulations Title 21. 2014. Available at http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CF....
-
- Block SL, Szenborn L, Daly W, et al. A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial. Vaccine. 2015;33:2500–10. - PubMed
-
- Kimura A, Toneatto D, Kleinschmidt A, Wang H, Dull P. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin Vaccine Immunol. 2011;18:483–6. - PMC - PubMed
-
- Read RC, Baxter D, Chadwick DR, et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet. 2014;384:2123–31. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical